Loading patent…
AssigneeGenmab A/S
InventorsChristian Reiter, Francois Habersetzer, Anne Fournillier, Christian Trepo, Claude Desgranges, Genevieve Inchauspe
Estimating the term…
Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable aof neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation.
1-21. (canceled)
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibody, wherein said antibody comprises at least a VH complementarity determining region (CDR) 3 (CDR3) having amino acids 98-106 of SEQ ID NO:
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibody, wherein said antibody specifically recognizes the same conformation-dependent epitope of Hepatitis C Virus (HCV) E2 present on HCV genotypes 1a, 1b, 2a, 3a and 4 as that bound by an antibody comprising at least a VH complementarity determining region (CDR) 3 (CDR3) having amino acids 98-106 of SEQ ID NO:
A method of treatment comprising administering a therapeutically effective amount of a pharmaceutical composition to a subject in need thereof, wherein said pharmaceutical composition comprises a pharmaceutically acceptable carrier and an antibody, which antibody comprises at least a VH complementarity determining region (CDR) 3 (CDR3) having amino acids 98-106 of SEQ ID NO:
A method of treatment comprising administering a therapeutically effective amount of a pharmaceutical composition to a subject in need thereof, said composition comprising a pharmaceutically acceptable carrier and an antibody, wherein said antibody specifically recognizes the same conformation-dependent epitope of HCV E2 present on HCV genotypes 1a, 1b, 2a, 3a and 4 as that bound by an antibody comprising at least a VH complementarity determining region (CDR) 3 (CDR3) having amino acids 98-106 of SEQ ID NO:
Dependencies are inferred from the claim text.